Novo Nordisk Raises Dosage in Weight Loss Drug Trial, Demonstrating Progress Yet Lagging Behind Eli Lilly's Competing Medication
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 15 2025
0mins
Should l Buy ?
Source: aastocks
Novo Nordisk's Clinical Trial Results: Novo Nordisk increased the dosage of its obesity treatment semaglutide to 7.2 mg in clinical trials, leading to an average weight loss of 19% over 72 weeks, compared to Eli Lilly's tirzepatide, which achieved 22.5% weight loss.
Market Implications: If priced competitively, the higher dosage of semaglutide could offer a more affordable alternative in the obesity treatment market, despite currently trailing behind Eli Lilly's results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
